Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

Welcome to the Papua New Guinea Kina exchange rate & live currency converter page. The Papua New Guinea Kina (PGK) exchange rates represented on this page are live, updated every minute within the ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. The full ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD, or mild cognitive impairment due to ...

Given below is the dialing procedure to call Papua New Guinea From Australia. You will find information on how to make an international call from Australia to Papua New Guinea fixed line number or ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Q: What is the Dollar worth against the Papua New Guinea Kina? A: One Dollar is worth 4.0108 Papua New Guinea Kina today Q: Is the Dollar going up or down against the Papua New Guinea Kina?

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly three months after it recommended approval for the drug to treat some ...